Satellos Bioscience (MSLE) EPS (Basic) (2025 - 2026)
Satellos Bioscience's (MSLE) quarterly EPS (Basic) came in at -$0.53 in Q1 2026, down 220.91% year-on-year from $0.44 in Q1 2025, and down 220.91% on a QoQ basis from $0.44 in Q1 2025.
Satellos Bioscience (MSLE) EPS (Basic) (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has 2 years of EPS (Basic) data on file, last reported at -$0.53 in Q1 2026.
- On a quarterly basis, EPS (Basic) fell 220.91% year-over-year to -$0.53 in Q1 2026; TTM through Mar 2026 was -$0.2, a N/A change from a year earlier, with the FY2025 full-year figure at -$1.71, up 19.04% from the prior year.
- EPS (Basic) for Q1 2026 stood at -$0.53, down from $0.44 in the prior quarter.
- Over the last five years, EPS (Basic) for MSLE reached as high as $0.44 in Q1 2025 and fell as low as -$0.53 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 0.00 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.16 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 0.00 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 4.06 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 6.99 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 0.00 |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 7.59 |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -2.29 |
| 10 | Satellos Bioscience | 148.71 Mn | 148.71 Mn | - | -0.53 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.53 |
| Mar 31, 2025 | 0.44 |